Roche submits multiple sclerosis drug fenebrutinib to regulators despite patient deaths

By Marleen Kaesebier and Patricia Weiss ZURICH, April 22 (Reuters) - Swiss drugmaker Roche on Wednesday said it was ...
Hosted on MSN

How a multiple sclerosis drug reshapes the immune system

When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered patients immense hope. The long-awaited drug is a monoclonal antibody that ...

Roche to seek regulatory review for multiple sclerosis drug despite fatalities

Roche (RHHBF) (RHHBY) has announced plans to seek regulatory review for an experimental therapy for multiple sclerosis, an autoimmune condition affecting the central nervous system, even as its ...
AOL

FDA Delays Key Sanofi Multiple Sclerosis Drug Decision

On Monday, the U.S. Food and Drug Administration (FDA) extended the review date for Sanofi SA’s (NASDAQ:SNY) new drug application (NDA) of tolebrutinib for non-relapsing, secondary progressive ...
Yahoo

Roche's MS drug candidate meets primary goal in late-stage trial

FRANKFURT (Reuters) -Swiss drugmaker Roche said on Monday that a late-stage trial testing ‌its multiple sclerosis drug candidate fenebrutinib against the relapsing form ‌of the disease achieved its ...
Seeking Alpha

BioNxt Reports Sublingual Cladribine Multiple Sclerosis Drug Milestones Including Large-Animal Study for Validation and Dosing Optimization

VANCOUVER,BC / ACCESS Newswire / September 29, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery ...
AOL

Roche's multiple sclerosis drug fenebrutinib meets goal in late-stage trial

The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File Photo BERLIN, Feb 7 (Reuters) - Swiss pharmaceutical company Roche said ...
UPI

Experimental drug shown to slow multiple sclerosis disability

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib, delayed ...
MarketWatch

Sanofi stock slumps after two setbacks on multiple-sclerosis drug

Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t be completed by the end of the year and a trial for a different form of MS ...
Morningstar

Sanofi Shares Fall After Multiple Sclerosis Drug Gets Hit by Double Setback

Sanofi shares fell after an experimental treatment for multiple sclerosis was hit by a double setback, with results of a late-stage study missing a key goal and U.S. regulators signaling a decision on ...
Benzinga.com

Contineum Therapeutics' Multiple Sclerosis Trial Disappoints, But Analyst Sees Other Assets Driving Value

Contineum Therapeutics, Inc. (NASDAQ: CTNM) on Thursday shared topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist for relapsing-remitting multiple sclerosis (RRMS). RRMS ...
Morningstar

Roche Multiple Sclerosis Drug Meets Key Goal in Late-Stage Trial

Roche Holding said a drug candidate for multiple sclerosis met the primary goal in a late-stage clinical trial in the most common form of the disease. The Swiss pharmaceutical company said Monday that ...